Latest Biotechnology News

Page 5 of 115
Noxopharm has halted trading in its securities while it prepares an announcement about a capital raising. The suspension is scheduled to last until the earlier of the announcement or the start of trading on 2 November 2026, unless ASX decides otherwise.
Ada Torres
Ada Torres
29 Oct 2026
INOVIQ will restart its EXO-OC ovarian cancer program through a staged optimisation and verification process after an independent review found sample collection and handling were the main sources of variability. The company is targeting US laboratory-developed test readiness in the first half of 2028, while a leadership change adds another moving part.
Ada Torres
Ada Torres
29 Oct 2026
PYC Therapeutics has moved all four RNA drug programs towards their next development milestones, while reporting $655 million in cash and treasury investments at 30 September. The company’s standalone cash balance covers just 1.13 quarters, making its liquid investment portfolio central to the stated funding runway through 2030.
Ada Torres
Ada Torres
29 Oct 2026
Dimerix has more than doubled its cash balance after an Everest Medicines licensing payment and a drawdown from a secured funding facility. The ASX-listed biotech is also advancing its fully recruited Phase 3 trial while preparing a second kidney drug for Phase 2 testing.
Ada Torres
Ada Torres
29 Oct 2026
Skin Elements has converted its New Zealand Farmlands agreement into a first NZ$150,000 ECO-Nurture delivery, while A$900,000 in placement proceeds lifted quarter-end cash to A$1.455 million. The commercial progress comes alongside a cost review and a regulatory hurdle still standing between the company and broader national sales.
Ada Torres
Ada Torres
29 Oct 2026
Immutep has identified structural differences between the efti used in its failed TACTI-004 Phase III trial and batches used in earlier successful studies, prompting a new 200 L manufacturing run. The biotech is narrowing efti’s future development focus while elevating autoimmune candidate IMP761 to co-priority status.
Ada Torres
Ada Torres
29 Oct 2026
Cambium Bio has moved Elate Ocular into Phase 3 manufacturing and submitted an updated CAMOMILE-2 protocol to the FDA. The company is targeting First Patient In by year-end, but that timetable depends on a conditional A$7.1 million placement, unsigned CRO agreements and release of the first clinical batch.
Ada Torres
Ada Torres
28 Oct 2026
Paradigm Biopharmaceuticals has secured court approval to delay its second creditors meeting until 27 January 2027, giving administrators more time to resolve outstanding matters. The meeting and administrators’ report could still arrive earlier, potentially within weeks.
Victor Sage
Victor Sage
28 Oct 2026
Biotron’s BIT-HBV001 produced up to a 99.7% reduction in HBV-DNA in cell-based studies, while combination testing with Myrcludex B showed antiviral synergy. The company is also refining SedRx’s European regulatory pathway, but had A$1.06 million in cash at quarter-end, equivalent to 2.15 quarters of funding at the latest operating burn rate.
Ada Torres
Ada Torres
28 Oct 2026
Avecho has resumed recruitment for the final cohort of its pivotal Phase III insomnia trial after an interim review supported continuing at the original 519-participant target. The biotechnology company is also pursuing international licensing while holding $5.3 million in cash.
Ada Torres
Ada Torres
28 Oct 2026
Amplia Therapeutics is preparing the next stage of narmafotinib’s pancreatic cancer development as its ACCENT trial nears completion and a Lilly collaboration broadens the drug’s potential into lung cancer. The biotech ended September with $20.8 million in cash, rising to $25.6 million pro forma after an October R&D tax refund.
Victor Sage
Victor Sage
28 Oct 2026
Neurotech International has dosed the first patient in its pivotal Phase 3 trial of NTI164, with all six Australian sites now active and up to 200 children planned for enrolment. The milestone sits alongside FDA clearance and fresh funding, but quarter-end cash covered only 1.24 quarters of historical operating outflows.
Ada Torres
Ada Torres
28 Oct 2026

Browse the archive

Full archive